 | |
| Clinical data | |
|---|---|
| Other names | PSK-3841; HMR-3841 |
| Drug class | Nonsteroidal antiandrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H18F3N3O3 |
| Molar mass | 369.344 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
RU-58841, also known asPSK-3841 orHMR-3841, is anonsteroidal antiandrogen (NSAA) which was initially developed in the 1980s byRoussel Uclaf, the French pharmaceutical company from which it received its name. It was formerly under investigation by ProStrakan (previously ProSkelia and Strakan) for potential use as atopical treatment forandrogen-dependent conditions includingacne,pattern hair loss,[1] andexcessive hair growth.[2][3][1] The compound is similar in structure to the NSAARU-58642 but contains a differentside-chain.[4] These compounds are similar inchemical structure tonilutamide,[5] which is related toflutamide,bicalutamide, andenzalutamide, all of which are NSAAs similarly.[6] RU-58841 can besynthesized either by building thehydantoinmoiety or byarylcoupling to 5,5-dimethylhydantoin.[7]
RU-58841 producescyanonilutamide (RU-56279) and RU-59416 asmetabolites in animals.[8] Cyanonilutamide has relatively low affinity for the androgen receptor but shows significantantiandrogenic activity in animals.[8] RU-59416 has very low affinity for the androgen receptor.[8]
